The HNF1A-AS1/miR-92a-3p Axis Affects the Radiosensitivity of Non-small Cell Lung Cancer by Competitively Regulating the JNK Pathway

Overview

Journal Cell Biol Toxicol

Publisher Springer

Specialties Cell Biology
Toxicology

Date 2021 Mar 23

PMID 33755848

Citations 21

Authors

Zhiyu Wang

Liang Liu

Yuankun Du

Yuan Mi

Lei Wang

Affiliations

Soon will be listed here.

Abstract

Background: It has been widely reported that long non-coding RNAs (lncRNAs) could affect the varieties of tumor response to radiotherapy. LncRNA HNF1A-AS1 is transcribed from HNF1A gene cluster's antisense strand. This work focused on the mechanism of how HNF1A-AS1 participated in the radiosensitivity of non-small cell lung cancer (NSCLC).

Methods: The mRNA or protein expression of HNF1A-AS1, miR-92a-3p MAP2K4, and JNK in NSCLC cells and tissues was detected by qRT-PCR or western blotting. RNA immunoprecipitation (RIP) detection and luciferase reporting system were used to evaluate the relationship between HNFA-AS1 and miR-92a-3p or between miR-92a-3p and MAP2K4. Flow cytometry assays, colony formation, and MTT were performed to analyze the function changes in A549 and Calu-1 cells. The rescue experiment was also conducted to explore the underlying mechanisms.

Results: HNF1A-AS1 was investigated in NSCLC cells and tissues and highly related to the advanced pathological stage. HNF1A-AS1 bound with miR-92a-3p, which was downregulated in NSCLC. It showed that miR-92a-3p was negatively related to HNF1A-AS1. Knockdown of HNF1A-AS1 impacted most cell biological behaviors in NSCLC cells, including restricting the proliferation and aggravating apoptosis. Furthermore, knockdown of HNF1A-AS1 dramatically enhanced radiotherapy sensitivity of NSCLC. Moreover, miR-92a-3p was found to target MAP2K4 and could reduce MAP2K4 expression. Inhibition of HNF1A-AS1 elevated radiotherapy sensitivity and retarded the progression of NSCLC cells, followed by decreasing expression levels of MAP2K4. Besides, MAP2K4 mimic rescued the si-HNF1A-AS1 effects on the biological behavior of NSCLC cells.

Conclusion: HNF1A-AS1 is highly expressed in NSCLC. MiR-92a-3p is the target gene of HNF1A-AS1 and involved in tumor progression by regulating the MAP2K4/JNK pathway. HNF1AS1/miR-92a-3p/MAP2K4 axis plays important roles in radiotherapy resistance of NSCLC.

Citing Articles

HNF1A-AS1 promotes oral squamous cell carcinoma progression via regulating miR-138/CDK6 pathway.

Mei B, Zeng Z, Xia Q, Liu M, Lei L Odontology. 2025; .

PMID: 39953309 DOI: 10.1007/s10266-025-01057-w.

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.

DNA damage response-related ncRNAs as regulators of therapy resistance in cancer.

Gao Z, Luan X, Wang X, Han T, Li X, Li Z Front Pharmacol. 2024; 15:1390300.

PMID: 39253383 PMC: 11381396. DOI: 10.3389/fphar.2024.1390300.

Current knowledge of antisense long non-coding RNA in the occurrence and prognosis of skull base tumors.

Zhang H, Lv Q, Zheng Z, Shen L, Zhou J, Xu Q Heliyon. 2024; 10(16):e35960.

PMID: 39224262 PMC: 11367136. DOI: 10.1016/j.heliyon.2024.e35960.

Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications.

Si C, Gao J, Ma X Mol Cancer. 2024; 23(1):134.

PMID: 38951879 PMC: 11218398. DOI: 10.1186/s12943-024-02045-4.

References

Bai Y, Liu X, Qi X, Liu X, Peng F, Li H . PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine. 2019; 42:311-325. PMC: 6491656. DOI: 10.1016/j.ebiom.2019.03.045. View

Baker S, Dahele M, Lagerwaard F, Senan S . A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. 2016; 11(1):115. PMC: 5012092. DOI: 10.1186/s13014-016-0693-8. View

Brown S, Banfill K, Aznar M, Whitehurst P, Faivre Finn C . The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol. 2019; 92(1104):20190524. PMC: 6913359. DOI: 10.1259/bjr.20190524. View

Cai L, Lv J, Zhang Y, Li J, Wang Y, Yang H . The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma. J Cell Mol Med. 2017; 21(11):2654-2662. PMC: 5661255. DOI: 10.1111/jcmm.12944. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Cun J, Yang Q . Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Biomed Pharmacother. 2018; 107:117-128. DOI: 10.1016/j.biopha.2018.07.158. View

Dang Y, Lan F, Ouyang X, Wang K, Lin Y, Yu Y . Expression and clinical significance of long non-coding RNA HNF1A-AS1 in human gastric cancer. World J Surg Oncol. 2015; 13:302. PMC: 4608159. DOI: 10.1186/s12957-015-0706-3. View

Dykes I, Emanueli C . Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. Genomics Proteomics Bioinformatics. 2017; 15(3):177-186. PMC: 5487525. DOI: 10.1016/j.gpb.2016.12.005. View

Fang C, Qiu S, Sun F, Li W, Wang Z, Yue B . Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. Cancer Lett. 2017; 410:50-62. DOI: 10.1016/j.canlet.2017.09.012. View

10.

Feng Z, Wang B . Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer. Oncol Lett. 2018; 15(4):4535-4540. PMC: 5835864. DOI: 10.3892/ol.2018.7878. View

11.

Jin H, Hong S, Park J, Chang Y, Hong Y, Park I . Inhibition of JNK-mediated autophagy enhances NSCLC cell sensitivity to mTORC1/2 inhibitors. Sci Rep. 2016; 6:28945. PMC: 4928093. DOI: 10.1038/srep28945. View

12.

Liu H, Liu S, Liu L, Ma R, Gao P . EGR1-Mediated Transcription of lncRNA-HNF1A-AS1 Promotes Cell-Cycle Progression in Gastric Cancer. Cancer Res. 2018; 78(20):5877-5890. PMC: 6191331. DOI: 10.1158/0008-5472.CAN-18-1011. View

13.

Liu L, Chen Y, Li Q, Duan P . lncRNA HNF1A-AS1 modulates non-small cell lung cancer progression by targeting miR-149-5p/Cdk6. J Cell Biochem. 2019; 120(11):18736-18750. DOI: 10.1002/jcb.29186. View

14.

Luo D, Liu D, Shi W, Jiang H, Liu W, Zhang X . PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner. Oncogenesis. 2019; 8(10):53. PMC: 6760234. DOI: 10.1038/s41389-019-0162-y. View

15.

Luo X, Wei J, Yang F, Pang X, Shi F, Wei Y . Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int. 2019; 19:323. PMC: 6889431. DOI: 10.1186/s12935-019-1042-4. View

16.

Ou J, Pan F, Geng P, Wei X, Xie G, Deng J . Silencing fibronectin extra domain A enhances radiosensitivity in nasopharyngeal carcinomas involving an FAK/Akt/JNK pathway. Int J Radiat Oncol Biol Phys. 2012; 82(4):e685-91. DOI: 10.1016/j.ijrobp.2011.09.040. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

18.

Venza M, Visalli M, Beninati C, Benfatto S, Teti D, Venza I . miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. Int Immunopharmacol. 2016; 40:235-243. DOI: 10.1016/j.intimp.2016.09.004. View

19.

Wang C, Mou L, Chai H, Wang F, Yin Y, Zhang X . Long non-coding RNA HNF1A-AS1 promotes hepatocellular carcinoma cell proliferation by repressing NKD1 and P21 expression. Biomed Pharmacother. 2017; 89:926-932. DOI: 10.1016/j.biopha.2017.01.031. View

20.

Whitmarsh A, Davis R . Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007; 26(22):3172-84. DOI: 10.1038/sj.onc.1210410. View